

# CLINICAL IMMUNOANALYZER MARKETS

*(SAMPLE COPY, NOT FOR RESALE)*



**TABLE OF CONTENTS**

1. Overview	7
1.1 Objectives	7
1.2 Methodology	8
1.3 Scope of the Report	9
1.4 Executive Summary	10
2. IVD Clinical Immunoanalyzer Market	12
2.1 Introduction	12
3. IVD Clinical Immunoanalyzer Market Analysis	15
3.1 Markets	15
3.1.1 Global Markets	15
3.1.2 Global Drivers of Clinical Immunoanalyzer Testing	16
3.1.3 Global Outlook	17
3.1.4 U.S. Market	18
3.1.5 European IVD Market	20
3.1.5.1 German Clinical Immunoanalyzer Diagnostic Market	22
3.1.5.2 U.K. Clinical Immunoanalyzer Testing Diagnostic Market	24
3.1.5.3 French Clinical Laboratory Diagnostic Testing Market	25
3.1.5.4 Italian Clinical Immunochemistry Diagnostic Market	25
3.1.5.5 Spanish Immunoanalyzer Market	26
3.1.5.6 Finnish Immunoanalyzer Market	26
3.1.5.7 Belgian Immunoanalyzer Market	27
3.1.5.8 Swiss Immunoanalyzer Market	27
3.1.5.9 Dutch Immunoanalyzer Market	28
3.1.5.10 Portuguese Immunoanalyzer Market	28
3.1.5.11 Austrian Immunoanalyzer Market	29
3.1.5.12 Greek Immunoanalyzer Market	29
3.1.5.13 Polish Immunoanalyzer Market	30
3.1.5.14 Romanian Immunoanalyzer Market	30
3.1.6 Country Clinical Analyzer Smaller Markets	31
3.1.6.1 Canadian Clinical Analyzer Market	31
3.1.6.2 Brazilian Clinical Analyzer Market	31
3.1.6.3 Turkish Clinical Immunoanalyzer Market	32
3.1.6.4 Australian Clinical Analyzer Market	32
3.1.6.5 Rest of the World Clinical Analyzer Testing Market	33
3.1.7 Overview of Asian Healthcare Market	33
3.1.7.1 Japanese Clinical Immunoanalyzer Testing Market	33
3.1.7.2 Chinese Clinical Analyzer Market	34
3.1.7.3 Indian Clinical Chemistry Diagnostic Market	44
3.1.7.3.1 India's In Vitro Diagnostic Testing Industry	44
3.1.8 Overview of the Latin American Diagnostics Market	48
3.2 Clinical Immunoanalyzer Sector	48
3.2.1 Industry-served Markets	49
3.2.2 Industry Players	52
3.2.2.1 Manufacturing Companies	52
3.2.3 Market Specialization	53
3.2.4 Revenue and Reimbursement	55
3.2.5 Companies	55
3.3 Outlook for Clinical Immunoanalyzer Testing	57
3.3.1 Long-term Changes	57
3.3.2 Market Drivers	58
3.3.3 The Limits to Growth	58

3.3.4	Hot Sectors in IVD Market	59
3.3.5	Key Technologies	59
3.3.6	Analyzer Integration Chemistry/Immunoassay	60
3.3.7	Conclusion	61
4.	Clinical Immunoanalyzer Instrument Market by Sector	62
4.1	Market Analysis: Size, Growth, Share and Competitors	62
4.1.1	Immunochemistry Analyzers	62
4.1.2	Large- and Mid-Volume Immunochemistry Analyzers	62
4.1.2.1	Abbott Diagnostics	62
4.1.2.2	Siemens Medical Solutions Diagnostics	64
4.1.2.3	Beckman Coulter, Inc.	69
4.1.2.4	Dade Behring (Acquired by Siemens)	71
4.1.2.5	Diagnostics Products Corporation (Acquired by Siemens Healthcare Diagnostics)	71
4.1.2.6	Olympus America, Inc. (now Beckman Coulter)	73
4.1.2.7	Ortho-Clinical Diagnostics	74
4.1.2.8	Roche Diagnostics Corp.	76
4.1.2.9	Tosoh Bioscience, Inc.	78
4.1.3	Batch-type Immunoassay Analyzers	80
4.1.3.1	Bio-Rad	80
4.1.3.2	Diamedix	80
4.1.3.3	Tosoh	83
4.1.4	Small- to Mid-Volume Immunoassay Analyzers	83
4.1.4.1	Awareness Technology, Inc.	83
4.1.4.2	Siemens Healthcare Diagnostics, Inc.	83
4.1.4.3	Beckman Coulter, Inc.	84
4.1.4.4	bioMérieux SA	85
4.1.4.5	Dade Behring (Acquired by Siemens)	85
4.1.4.6	Randox Laboratories Ltd.	89
4.1.4.7	Tosoh Corporation	90
4.1.5	Other Immunoassay Analyzers	91
4.1.5.1	Inverness Medical Professional Diagnostics	91
4.1.5.2	Hycor BioMedical (A Part of Agilent Technologies)	91
4.1.5.3	Phadia AB	92
4.1.5.4	Trinity Biotech Plc	92
4.1.5.5	DiaSorin	92
4.1.5.6	Grifols U.S.A., Inc.	92
4.1.5.7	Bio-Rad Laboratories, Inc.	93
4.1.5.8	SFRI Diagnostics	93
4.1.5.9	Qualigen, Inc.	93
4.1.5.10	PerkinElmer, Inc.	93
4.1.5.11	Innotrac Diagnostics Oy	94
4.1.5.12	Tecan Group Ltd.	94
5.	Important Technology Trends	96
5.1	Technology Innovations in Immunoassay Testing	96
5.2	Immunoassay Detection Technology Platforms	96
5.2.1	Fluorescence Detection	97
5.2.2	Chemiluminescence Detection	97
5.3	The New Paradigm	97
5.4	Consolidated Workstations	97
5.5	Automation in the Laboratory in Response to Labor Shortages	99
5.6	Laboratory Information System (LIS)	100
5.7	Biosensor Technology	100
5.8	Data Management Issues	102

- 5.8.1 Wireless LANs 103
  - 5.8.2 Data and Workflow Management Systems 104
  - 5.8.3 Beckman Central Command 104
  - 5.8.4 Advances in Information Management 106
  - 5.8.5 Connectivity Platforms 109
    - 5.8.5.1 Laboratory Data Linking Software and Interface to the Laboratory Information System 111
    - 5.8.5.2 Abbott Link Analyzer Connections 111
    - 5.8.5.3 Beckman Coulter DL2000 Data Manager v6.5 112
    - 5.8.5.4 bioMérieux, Inc. ENQ 112
    - 5.8.5.5 Ortho-Clinical Diagnostics, Inc. e-Connectivity Interactive System Management 113
  - 5.8.6 DataLink Data Management System 113
  - 5.8.7 LifeScan Electronic Data Interfaces 114
  - 5.8.8 Technical Problems of Connectivity 115
  - 5.8.9 Web-based Data Interface and Internet Connectivity 116
  - 5.8.10 HIT Competition 117
  - 5.8.11 FDA-required Software Verification 117
  - 5.8.12 Advantages of Connectivity 118
  - 5.8.13 Technologies for Internet-based Remote Architecture 118
  - 5.8.14 Abbott Multi-tiered Internet System 118
6. Business Trends in Clinical Immunoanalyzer Sector 119
- 6.1 Key Developments 119
  - 6.2 Sector Consolidation 119
  - 6.3 Diagnostic Testing Growth Trends 120
  - 6.4 Reagents and Hardware Business in Japan 120
  - 6.5 New Products 120
  - 6.6 Acquisitions, License Agreements, Internal Developments and Partnerships 121
  - 6.7 Product Testing Depth in Clinical Immunoanalyzer Testing 122
  - 6.8 Government Regulations 122
    - 6.8.1 U.S. Government Regulations 122
      - 6.8.1.1 Importing Medical Devices into the U.S. 124
      - 6.8.1.2 Exporting Medical Devices from the U.S. 124
    - 6.8.2 U.K. Regulations 125
    - 6.8.3 E.U. Regulations 126
    - 6.8.4 Japanese Regulations 127
    - 6.8.5 Korean Regulations 128
  - 6.9 Increased Market Penetration 128
  - 6.10 Costs of Doing Business in Europe 130
  - 6.11 Drivers of European Diagnostics Testing 130
  - 6.12 European Reimbursement Practices 130
  - 6.13 Cost Containment in Europe 130
  - 6.14 Medicare Spending Trends/Medicare Part B Spending Trends 131
  - 6.15 Connectivity Consortium 133
7. Company Profiles 134
- 7.1 Abbott Diagnostics 134
  - 7.2 Beckman Coulter, Inc. 138
  - 7.3 bioMérieux 140
  - 7.4 Dade Behring (Acquired by Siemens) 140
  - 7.5 Bio-Rad Laboratories, Inc. 140
  - 7.6 Olympus America, Inc. 141
  - 7.7 Ortho-Clinical Diagnostics, Inc. 141
  - 7.8 Phadia AB 142
  - 7.9 Randox Laboratories Ltd. 142
  - 7.10 Roche 143

7.11 Tosoh Corporation	144
7.12 Siemens AG	145
8. Clinical Immunoanalyzer Testing Sector: Trends and Forecasts	147
8.1 Automated Instrument Platforms Evolution	147
8.2 Reagents and Supplies Market for Clinical Lab Instruments	147
8.3 Bar Code Reading	148
8.4 Measurement and Detection for Immunoassay Analyzers	148
8.5 Robotics Systems	149
8.6 Move Away from Central Laboratory	150
8.7 Modular Automation	150
8.8 Components of Immunoassay Analyzers	150
8.8.1 The User Interface	151
8.8.2 Display and Data Entry	151
8.8.3 Loading and Unloading	151
8.8.4 Sample Input and Handling	151
8.8.5 Fluidics	152
8.8.6 Processing	153
8.8.6.1 Agitation and Mixing	153
8.8.6.2 Temperature Control and Incubation	153
8.8.6.3 Separation	153
8.8.7 Control and Communications	153
8.8.7.1 Instrument Control	154
8.8.7.2 Scheduling	154
8.8.7.3 Communications and Data Management	154
8.9 Drivers of Clinical Immunoanalyzer Testing	155
8.10 Confluence of New Technology	155
8.11 New Trends in Clinical Laboratory Testing	155
8.11.1 Trends in Reimbursement Practices	155
8.11.2 Managed Care	158
8.11.3 Changes in Patient Management	158
8.11.4 Focused Testing	159
8.11.5 Spending for Clinical Laboratory Testing	159
8.11.6 Reimbursement Pressure	159
8.11.7 Multiplexing Technology	159
9. Product Launches	161
9.1 Immunoassay Analyzer Product Launches	161
9.2 Immunoassay Reagent Product Launches	162

## INDEX OF FIGURES

Figure 3.1: Chinese IVD Market, 2006-2012	37
Figure 3.2: Lab Revenue by Lab Type	50
Figure 3.3: Lab Revenue by Test Type	51
Figure 6.1: Part B Spending on Clinical Laboratory Services, 1991- 2007	131

## INDEX OF TABLES

Table 2.1: Common Immunoassay Tests	12
Table 3.1: Worldwide IVD Testing Market, 2009	15
Table 3.2: Worldwide Geographic Distribution of IVD Testing, 2009	15
Table 3.3: Global Clinical Immunoassay Revenues, 2000-2012	16

Table 3.4: Worldwide Distribution of Clinical Immunoassay Testing, 2009	16
Table 3.5: U.S. Clinical Laboratory Testing Market, 2003-2012	19
Table 3.6: U.S. Clinical Laboratory Diagnostic Test Market Retail Value Segments, 2008	19
Table 3.7: U.S. Clinical Immunoanalyzer Testing Market, 2009-2015	19
Table 3.8: European Clinical Laboratory Testing IVD Reagents and Instruments Market, 2000-2012	20
Table 3.9: European Clinical Laboratory Diagnostic Reagents and Instruments Markets by Analyte, 2008	20
Table 3.10: European Clinical Laboratory Testing Diagnostics by Country Market Estimates, 2007	21
Table 3.11: The European Immunochemistry Market, 2001-2012	21
Table 3.12: European Immunochemical Reagents and Instruments Markets by Country, 2006	22
Table 3.13: German Clinical Laboratory Testing Diagnostics Products Market Sales, 2003-2012	23
Table 3.14: German Clinical Immunochemistry Testing Diagnostics Products Market Sales, 2006-2012	23
Table 3.15: U.K. Clinical Immunochemistry Testing Diagnostics Products Market Sales, 2006-2012	24
Table 3.16: French Clinical Immunochemistry Testing Diagnostics Products Market Sales, 2006-2012	25
Table 3.17: Italian Immunochemistry Diagnostics Products Market Sales, 2006-2012	25
Table 3.18: Spanish Clinical Laboratory Diagnostics Products Market Sales, 2006-2012	26
Table 3.19: Finnish Clinical Immunoassay Products Market Sales, 2006-2012	26
Table 3.20: Belgian Clinical Immunoassay Products Market Sales, 2006-2012	27
Table 3.21: Swiss Clinical Immunoassay Products Market Sales, 2006-2012	27
Table 3.22: Dutch Clinical Immunoassay Products Market Sales, 2006-2012	28
Table 3.23: Portuguese Clinical Immunoassay Products Market Sales, 2006-2012	28
Table 3.24: Austrian Clinical Immunoassay Products Market Sales, 2006-2012	29
Table 3.25: Greek Clinical Immunoassay Products Market Sales, 2006-2012	29
Table 3.26: Polish Clinical Immunoassay Products Market Sales, 2006-2012	30
Table 3.27: Romanian Clinical Immunoassay Products Market Sales, 2006-2012	30
Table 3.28: Canadian Clinical Analyzer Testing Market, 2000-2009	31
Table 3.29: Brazilian Clinical Immunoanalyzer Testing Market, 2000-2009	31
Table 3.30: Turkish Clinical Analyzer Testing Market, 2000-2009	32
Table 3.31: Australian Clinical Immunoanalyzer Testing Market, 2000-2009	32
Table 3.32: ROW Clinical Immunoanalyzer Testing Market, 2000-2009	33
Table 3.33: Japanese Clinical Immunoanalyzer Testing Market, 2000-2009	33
Table 3.34: Drivers of Growth in the Chinese Clinical Laboratory Market	34
Table 3.35: Number of Chinese Medical Institutions	35
Table 3.36: Chinese Clinical Diagnostic Products Market, 2000-2008	35
Table 3.37: Chinese Clinical Laboratory Diagnostics Products Market Sales, 2003-2012	36
Table 3.38: Chinese IVD Market, 2008	36
Table 3.39: Market Share of Reagent Imports into the Chinese Clinical Lab Market by Country of Origin	40
Table 3.40: Market Share of Analytical Instrument Imports into the Chinese Clinical Lab Market by Country of Origin	40
Table 3.41: Chinese International IVD Manufacturers	40
Table 3.42: Chinese Domestic IVD Manufacturers	41
Table 3.43: Chinese IVD Distributors	43
Table 3.44: Indian IVD Market, 2006-2012	44
Table 3.45: Number of Automated Clinical Labs in India, 2004-2012	45
Table 3.46: Indian IVD Market, 2009	45
Table 3.47: Indian IVD Market for Instruments and Reagents, 2004-2012	47
Table 3.48: Estimated Number of Clinical Laboratories in Latin America	48
Table 3.49: U.S. Clinical Laboratory Testing Sector Revenue, 2005-2015	50
Table 3.50: U.S. Clinical Laboratory Testing Sector Segments, 2009	50
Table 3.51: Esoteric Tests Performed in the Clinical Laboratory	51
Table 3.52: Growth Rates of Test Types	52
Table 3.53: Drivers of Clinical Lab Testing Volume	52
Table 3.54: Principal Marketers of Automated Clinical Immunoanalyzer Instruments	52
Table 4.1: Samples and Sample Handling Features of Centaur CP	65
Table 4.2: Large- and Mid-Size Immunochemistry Analyzers	79
Table 4.3: Small- to Mid-Volume Immunoassay Analyzers	95

Table 5.1: Analytical Detection Levels for Drugs of Abuse	96
Table 5.2: Wireless LAN Technology Companies	103
Table 5.3: Applications for Wireless LAN Technology	104
Table 5.4: Key Benefits of Laboratory Connectivity Platforms	110
Table 5.5: Connectivity Interface Platforms for Clinical Chemistry Analyzers	110
Table 5.6: CAP and JCAHO Requirements for Customized Reporting	114
Table 6.1: Hospital Laboratory Share of Part B Medicare Spending, 1996-2006	132
Table 6.2: Medicare Part B Spending Per Medicare Enrollee, 1998-2009	132
Table 6.3: Allowed Charges for Top 25 Clinical Laboratory Procedures, 2009	133
Table 8.1: Technology Platforms for Analyzer Detection Systems	148
Table 8.2: Key Criteria for Assessing Data Management Capabilities of Automated Instruments for Immunochemistry Testing	155
Table 8.3: Medicare Billing Guidelines for Multi-Channel Immunoanalyzer Tests	156

SAMPLE

## 1. Overview

Clinical immunoanalyzer analysis is one of the most important functions of clinical laboratory analysis. By all accounts, automated immunoassay testing is one of the most rapidly developing of the several traditional clinical laboratory sectors. Clinical immunoanalyzer analysis usually refers to determining the concentration or activity of protein, carbohydrate, lipid, enzyme or small molecule in easily collected body fluids, such as blood, serum, plasma or urine. However, it is not necessarily limited to these purposes. The analysis of virtually any biologically active substance in any place in the body can generally be defined as clinical immunoassay testing. In fact, traditional specialization barriers, such as microbiology, hematology, blood banking, immunology and even anatomical pathology are fading rapidly, both operationally and instrumentally. This report deals with the traditional scope of clinical immunoassay, while looking at the emerging technology trends in this sector.

### 1.1 Objectives

The purpose of this study is to describe the specific segments of the global clinical immunoanalyzer instrumentation market. Within this area, the highly-active segments in terms of innovation and growth are covered. Specifically, it examines the markets for small labs and highly-automated large lab platforms, as well as the market for accessory equipment, such as reagents and supplies. Emphasis is on those companies and products that are actively developing and marketing immunoanalyzer products for clinical setting, including hospitals, independent labs, physician's offices and clinics.

This study focuses on the clinical immunoanalyzer instrumentation industry market segment in the United States and around the world. Specifically, this study examines the markets for small lab and highly-automated, large lab platforms, as well as accessory equipment such as reagents, supplies and manufacturers' original equipment manufacturer (OEM) equipment. The emphasis is on those companies and products that are actively developing and marketing chemistry analyzer products for the clinical setting, including hospitals, independent labs, physician's offices and clinics. The regional markets and their differences are examined *vis-à-vis* Europe, Japan and the rest of the world (ROW). Particular attention has been paid to those areas of the clinical immunoanalyzer instrumentation sector that are showing the greatest growth or innovation. Among other things, the report attempts to answer the following questions:

- Which companies are the key players?
- What are the opportunities in clinical immunoanalyzer instrumentation industry?
- What are the development trends?
- Where are the new market growth areas?
- What are the most favored technology platforms?
- Where is the immunoanalyzer instrumentation technology taking us?
- How is the immunological technology blending with the traditional chemistry analyzer?
- What is happening with the information revolution and its growing importance in connectivity issues?

The study surveys some of the leading companies known to be marketing, manufacturing or developing products for the clinical immunoanalyzer instrumentation market. Each company is discussed thoroughly with a section on the history of the company, product lines, marketing analyses, and a subjective commentary of the position of the company in the market. Readers can gain the following insights from this report:

- Complete analysis of the major sectors of the clinical immunoanalyzer instrumentation market, their size, growth rates and major drivers.
- Presentation of some of the emerging technology platforms, elucidating the potential areas that could gain traction in this market.
- Analysis of the partnerships and alliances that various key sector players have forged, including the financing linkages of these market participants, apart from insights into potential market collaborations.
- Examination of new technology platforms in the U.S., Japan and Europe that seek to dominate this mature market.



- Country market examinations of clinical chemistry sales volume, five year projections on sales and comments on local trends in the IVD markets.

## 1.2 Methodology

The author of this report is a Ph.D. in biochemistry from the University of Minnesota, with many decades of experience in scientific writing and as a medical industry analyst. He has been a senior director of several large regional and national healthcare laboratories. Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities like the U.S. Department of Health and Human Services (HHS) and U.S. federal agencies such as National Institutes of Health (NIH), Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

### *Primary Sources*

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark's research as part of this data collection.

### *Secondary Sources*

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

### *Market Forecasts and Modeling*

The numerical data on market size, growth rates and sales forecasts are obtained from a well-examined model based upon quantitative market information obtained from the leading global companies in the sector, private seminar presentations by company experts and public SEC filings. Many industry experts are also consulted to confirm these market estimates. The numbers used are washed of discounts and returns, and represent the final sale numbers. In addition, global numbers are assessed by region components as well, taking into account differences in market conditions between the U.S., Europe and Asian markets in particular.

### *TriMark Publications Report, Research and Data Acquisition Structure*

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.

- Formulating a study outline with the assigned writer, including important items, as follows:
  - Market and product segment grouping, and evaluating their relative significance.
  - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
  - End-user research to evaluate analytical significance in market estimation.
  - Supply chain research and analysis to identify any factors affecting the market.
  - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Launching a combination of primary research activities including two levels of questionnaires, executive-direct focused, company-specific, and region-specific communications to qualified and experienced senior executives worldwide.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

### 1.3 Scope of the Report

This study deals with the examination of analytes related to the constituents of blood, plasma or serum of patients that fall within the area of traditional immunoassay, as opposed to traditional clinical chemistry testing. Immunoassay tests are typically analytes like peptide, thyroid and steroid hormones, and biologically important proteins like immunoglobulins, alpha-1 anti-trypsin, calcitonin, lipids, carbohydrates, and so on. Typical immunoassay tests are discussed in the second section. The two most important places for conducting such tests are hospitals and independent clinical laboratories. Such tests are also measured in physician's office laboratories (POLs). Potential areas of testing interest for these analytes include satellite labs and corporate clinics.

The emphasis in this report is on those companies and products that are actively developing and marketing clinical laboratory instrumentation and reagents, and supplies for performing clinical immunoanalyzer tests in clinical diagnostics. The reader should consult other TriMark Publications reports at <http://www.trimarkpublications.com> for a detailed discussion of the important individual market segments that are related to the *in vitro* diagnostics (IVD) market, such as molecular diagnostic testing, high-growth diagnostic test markets, blood gas and electrolytes over-the-counter diagnostic testing markets, and point of care testing (POCT). The analysis touches on the specialty testing areas in clinical immunoanalyzer diagnostic testing, such as C-reactive protein (CRP), lipoprotein profiling and cardiac markers as these segments are frequently a part of the overall analytical focus of companies marketing general laboratory automation equipment. However, no effort is made to quantitate the size of this broader market.

The study also mentions companies that market and sell a limited number of instruments and equipment as an OEM part of a much larger clinical laboratory product line of other companies; for example, Hitachi's relationship with Roche Diagnostics Corporation; JEOL manufacturing products for Siemens; or Furuno Electric Co. and Polymedco, and their relationship with Randox. However, these companies are only reported *en passant* as they are not a direct focus of the clinical immunoanalyzer diagnostics instrument market.

This report does not cover what is generally characterized as chemistry instruments and reagents. What's more, it does not address hematology or coagulation markets—or other diagnostic device markets—although many of the instruments, reagents and techniques in the clinical immunoanalyzer diagnostics market segment are intimately associated with these broader areas. Moreover, this examination does not cover disposable plastic supplies for the clinical laboratory or blood gases and electrolytes. Although this analysis mentions recombinant proteins in passing—as well as techniques such as measuring the serum concentrations of therapeutic drugs and drugs of abuse—no extensive or complete treatment of this subject is presented. Such a discussion is outside the scope of this analysis.

## 1.4 Executive Summary

Clinical immunoanalyzer testing includes processes used to detect levels of enzyme, sugars, proteins and other substances in the blood in order to determine clinical conditions, such as nutritional state, liver function, kidney function and others. Immunoassay testing is widely applied in identifying conditions like arthritis, infectious diseases and thyroid diseases during clinical diagnoses and as a part of regular health checkups. During [REDACTED], approximately [REDACTED] clinical immunoanalyzer tests were carried out within hospitals in the U.S. Most of these tests were performed as screening or multi-channel tests using automated immunoanalyzers specifically designed for that purpose. Automated multi-channel testing addresses those tests that can be, and are, frequently done as groups and combinations on automated clinical immunoanalyzer equipment.

The global IVD reagent and instrument market for all test types was estimated to be \$ [REDACTED] in [REDACTED], up [REDACTED]% over the previous year, with the U.S., Europe and Asia comprising approximately [REDACTED]%, [REDACTED]% and [REDACTED]%, respectively, of the market. [REDACTED] countries account for approximately [REDACTED]% of the IVD market worldwide. [REDACTED] country markets account for [REDACTED]% of total IVD sales.

Many manufacturers are planning to launch new versions of automated chemistry analyzers during the analysis period, and this has become an ongoing process and an important marketing tool in the *in vitro* diagnostic industry. To meet the demand for increased onboard testing capacity, more types of clinical chemistry tests have been added, automation for quicker turnaround of results has been enhanced, user interfaces have been improved, and high-volume throughput has been underscored by design and marketing. Advanced concepts like modular analysis, consolidation of chemistry and immunoassay, ultra-integration, which combines four technologies that allow the user to process up to 100 methods simultaneously, and multiplexing are being introduced by manufacturers.

The top [REDACTED] companies control approximately [REDACTED]% of the total \$ [REDACTED] diagnostics industry. Siemens, BD, Abbott, Beckman and Roche Diagnostics continue to be top leaders. One company, Gen-Probe of San Diego, CA, has shown significant growth and has replaced the privately-held Instrumentation Laboratory in the top 13 largest IVD companies.

TriMark believes that the global IVD market will continue to grow due to a number of key favorable industry trends:

- Demographic shifts resulting from the aging of the population and socio-economic improvements are expected to increase the overall level of demand for diagnostic testing.
- Increased focus on lowering total healthcare expenditures will likely increase the demand for diagnostic testing as an effective tool to improve patient outcomes and to reduce the costs of misdiagnosis through earlier and more accurate diagnosis and patient monitoring.
- Emerging markets, especially in Asia and more specifically in China, will provide additional demand as economic improvements in several countries lead to increases in healthcare expenditures.
- Technology improvements in new tests, pathogens and markers will result in the increased use of diagnostics to aid in the diagnosis of diseases.
- Improvements in lower-cost point-of-care (POC) and/or near-patient testing capabilities are expected to expand the application of diagnostic testing capabilities into non-laboratory settings (*e.g.*, operating room, emergency room, acute care centers).
- Increased automation of diagnostic instruments is expected to lower the overall cost of diagnostic testing and thereby increase accessibility and demand.

The worldwide clinical chemistry instrument, reagent and supply segment of the IVD market was estimated by TriMark to be approximately \$ [REDACTED] in [REDACTED]. The sales of this market segment are projected by TriMark to \$ [REDACTED] by [REDACTED]. In addition to instrument sales and leasing, this includes consumable reagents for general chemistry, electrolytes, enzymes, blood gases, lipids and urinalysis, as well as disposable plastic products.

The distribution of clinical laboratory testing worldwide shows a preponderance of this type in North America and Europe. The European Union (E.U.), Japan and the U.S. currently make up about [REDACTED]% of the IVD market. This portion is expected to decrease to [REDACTED]% by [REDACTED] due to erosion of mature country market segments, and the expanding IVD markets in Asia, particularly China. In addition, IVD markets in South America and South Asia are

experiencing █% to █% annual growth rates. Japan, a very traditional country, has been slow to adapt clinical laboratory testing for point of care, considering its size as the second-largest economy in the world, and its position as manufacturer of many OEM laboratory instruments. The Japanese IVD market is forecast to grow by somewhat less than █% during the forecast period.

In the U.S., approximately █% of the \$██████████ U.S. clinical diagnostic testing retail value is currently conducted in hospital-based and commercial laboratories. In the U.S., approximately █% of clinical diagnostic testing is currently conducted in hospital-based and commercial laboratories.

Clinical immunoanalyzer testing now represents █% of the \$██████████ U.S. market for clinical diagnostic testing reagents, controls and equipment. This is projected to grow at an annual rate of █% in the U.S. through ████, to a total of \$██████████. Surveys show that █% of hospitals with more than ████ beds have adopted some form of clinical immunoanalyzer testing, with over █% of the ████ U.S. hospitals (██████ beds and larger) have installed some form of clinical immunoanalyzer instrumentation.

In the IVD industry, the E.U. accounted for █% of the world market for IVD products and had a total IVD market of \$██████████ (€██████████). With an expected real growth at a compound annual growth rate (CAGR) of █% to █% through ████, estimates suggest that the market for IVDs in the E.U. will reach \$██████████ by ████. The E.U. is second only to North America's █% market share of IVD products. TriMark finds that the IVD overall growth is projected to remain in the █% to █% range for the forecast period to ████.

The European immunoassay market increased significantly in ████ in most of the European countries (but not all) to €██████████, and the average growth was around █% in ████. Projections for the analysis period estimate the European immunoassay market in ████ at €██████████. Individual country markets for immunoassay analyzers and reagents are described.